These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21531821)

  • 1. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
    Faivre S; Zappa M; Vilgrain V; Boucher E; Douillard JY; Lim HY; Kim JS; Im SA; Kang YK; Bouattour M; Dokmak S; Dreyer C; Sablin MP; Serrate C; Cheng AL; Lanzalone S; Lin X; Lechuga MJ; Raymond E
    Clin Cancer Res; 2011 Jul; 17(13):4504-12. PubMed ID: 21531821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
    Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV
    Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
    Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
    Frampas E; Lassau N; Zappa M; Vullierme MP; Koscielny S; Vilgrain V
    Eur J Radiol; 2013 May; 82(5):e205-11. PubMed ID: 23273822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
    Luo Y; Chen J; Huang K; Lin Y; Chen M; Xu L; Li ZP; Feng ST
    BMC Cancer; 2017 Feb; 17(1):154. PubMed ID: 28231773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
    Wörns MA; Schuchmann M; Düber C; Otto G; Galle PR; Weinmann A
    Oncology; 2010; 79(1-2):85-92. PubMed ID: 21071995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Ronot M; Bouattour M; Wassermann J; Bruno O; Dreyer C; Larroque B; Castera L; Vilgrain V; Belghiti J; Raymond E; Faivre S
    Oncologist; 2014 Apr; 19(4):394-402. PubMed ID: 24652387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: comparison of RECIST, Choi and volumetric criteria.
    Schramm N; Englhart E; Schlemmer M; Hittinger M; Übleis C; Becker CR; Reiser MF; Berger F
    Eur J Radiol; 2013 Jun; 82(6):951-8. PubMed ID: 23518148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
    Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of sunitinib in advanced hepatocellular carcinoma.
    Barone C; Basso M; Biolato M; Pompili M; Rufini V; Miele L; Basso M; De Gaetano AM; Castaldi P; Iaculli A; Leccisotti L; Riccardi L; Grieco A
    Dig Liver Dis; 2013 Aug; 45(8):692-8. PubMed ID: 23410734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.
    Nathan PD; Vinayan A; Stott D; Juttla J; Goh V
    Cancer Biol Ther; 2010 Jan; 9(1):15-9. PubMed ID: 20009542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenic blockade and radiotherapy in hepatocellular carcinoma.
    Chi KH; Liao CS; Chang CC; Ko HL; Tsang YW; Yang KC; Mehta MP
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):188-93. PubMed ID: 20133077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.
    Faivre S; Raymond E; Boucher E; Douillard J; Lim HY; Kim JS; Zappa M; Lanzalone S; Lin X; Deprimo S; Harmon C; Ruiz-Garcia A; Lechuga MJ; Cheng AL
    Lancet Oncol; 2009 Aug; 10(8):794-800. PubMed ID: 19586800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
    Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
    Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
    van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Haanen JB; Boven E
    Br J Cancer; 2010 Mar; 102(5):803-9. PubMed ID: 20145618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
    Harmon CS; DePrimo SE; Raymond E; Cheng AL; Boucher E; Douillard JY; Lim HY; Kim JS; Lechuga MJ; Lanzalone S; Lin X; Faivre S
    J Transl Med; 2011 Jul; 9():120. PubMed ID: 21787417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of performance of various tumor response criteria in assessment of sunitinib activity in advanced gastrointestinal stromal tumors.
    Shinagare AB; Barysauskas CM; Braschi-Amirfarzan M; O'Neill AC; Catalano PJ; George S; Ramaiya NH
    Clin Imaging; 2016; 40(5):880-4. PubMed ID: 27179958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).
    Koeberle D; Montemurro M; Samaras P; Majno P; Simcock M; Limacher A; Lerch S; Kovàcs K; Inauen R; Hess V; Saletti P; Borner M; Roth A; Bodoky G
    Oncologist; 2010; 15(3):285-92. PubMed ID: 20203173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.